Positive news from the laboratory was the wind beneath the wings of Novo Nordisk (NYSE: NVO) stock on Thursday. The Denmark-based pharmaceutical company, famed for its Ozempic and Wegovy drugs ...

Novo Nordisk has added another dimension to its artificial intelligence ambitions by signing up as a customer of Denmark’s first so-called “supercomputer.”. The supercomputer, named Gefion ...

Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to develop drugs for cardiometabolic diseases, including obesity, the ...

Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years.

A Novo Nordisk iniciou um novo estudo em estágio avançado para seu candidato experimental de próxima geração no tratamento da obesidade, o CagriSema, em uma tentativa de tranquilizar o mercado quanto ...

Wegovy and Ozempic maker Novo Nordisk (NYSE: NVO) saw its stock price tick up slightly on Monday, on a media report about the possible entry of an activist investor. Market players cautiously bid ...

About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This ...

Novo Nordisk is expected to post earnings of $0.88 per share for the current quarter, representing a year-over-year change of +35.4%. Over the last 30 days, the Zacks Consensus Estimate has ...

Much like the long-term users of its most popular product, Novo Nordisk's (NYSE: NVO) stock has slimmed down considerably of late. Share prices of the company, which developed and sells weight ...